GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » EV-to-Revenue

Theralase Technologies (TSXV:TLT) EV-to-Revenue : 46.11 (As of Jun. 03, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Theralase Technologies's enterprise value is C$47.68 Mil. Theralase Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was C$1.03 Mil. Therefore, Theralase Technologies's EV-to-Revenue for today is 46.11.

The historical rank and industry rank for Theralase Technologies's EV-to-Revenue or its related term are showing as below:

TSXV:TLT' s EV-to-Revenue Range Over the Past 10 Years
Min: 11.23   Med: 34.96   Max: 118.25
Current: 46.11

During the past 13 years, the highest EV-to-Revenue of Theralase Technologies was 118.25. The lowest was 11.23. And the median was 34.96.

TSXV:TLT's EV-to-Revenue is ranked worse than
94.3% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.09 vs TSXV:TLT: 46.11

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Theralase Technologies's stock price is C$0.19. Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00. Therefore, Theralase Technologies's PS Ratio for today is 47.50.


Theralase Technologies EV-to-Revenue Historical Data

The historical data trend for Theralase Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EV-to-Revenue Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.40 93.40 59.92 37.69 63.59

Theralase Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.69 36.49 54.41 42.24 63.59

Competitive Comparison of Theralase Technologies's EV-to-Revenue

For the Medical Devices subindustry, Theralase Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EV-to-Revenue falls into.


;
;

Theralase Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Theralase Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=47.679/1.034
=46.11

Theralase Technologies's current Enterprise Value is C$47.68 Mil.
Theralase Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies  (TSXV:TLT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Theralase Technologies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.19/0.004
=47.50

Theralase Technologies's share price for today is C$0.19.
Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 3rd Quarter Trades of Barry Investment Advisors, LLC

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 2nd Quarter Trades of Pinnacle Wealth Management, LLC

By GuruFocus Research GuruFocus Editor 07-29-2022

Top 5 2nd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 08-15-2022

Top 5 4th Quarter Trades of Financial Sense Advisors, Inc.

By GuruFocus Research GuruFocus Editor 02-07-2023

Strong Tower Advisory Services Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-21-2023

Louis Moore Bacon Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-14-2022

Top 5 3rd Quarter Trades of Eqis Capital Management, Inc.

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 4th Quarter Trades of Starfox Financial Services, LLC

By GuruFocus Research GuruFocus Editor 02-08-2023

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-21-2023

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-24-2023